208 related articles for article (PubMed ID: 33964987)
1. β1-blocker in sepsis.
Hasegawa D; Sato R; Nishida O
J Intensive Care; 2021 May; 9(1):39. PubMed ID: 33964987
[TBL] [Abstract][Full Text] [Related]
2. Effect of Ultrashort-Acting β-Blockers on Mortality in Patients With Sepsis With Persistent Tachycardia Despite Initial Resuscitation: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Hasegawa D; Sato R; Prasitlumkum N; Nishida K; Takahashi K; Yatabe T; Nishida O
Chest; 2021 Jun; 159(6):2289-2300. PubMed ID: 33434497
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic and anti-inflammatory effects of early esmolol use in hyperkinetic septic shock: a pilot study.
Levy B; Fritz C; Piona C; Duarte K; Morelli A; Guerci P; Kimmoun A; Girerd N
Crit Care; 2021 Jan; 25(1):21. PubMed ID: 33413583
[TBL] [Abstract][Full Text] [Related]
4. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial.
Unger M; Morelli A; Singer M; Radermacher P; Rehberg S; Trimmel H; Joannidis M; Heinz G; Cerny V; Dostál P; Siebers C; Guarracino F; Pratesi F; Biancofiore G; Girardis M; Kadlecova P; Bouvet O; Zörer M; Grohmann-Izay B; Krejcy K; Klade C; Krumpl G
Trials; 2018 Nov; 19(1):637. PubMed ID: 30454042
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.
Kakihana Y; Nishida O; Taniguchi T; Okajima M; Morimatsu H; Ogura H; Yamada Y; Nagano T; Morishima E; Matsuda N;
Lancet Respir Med; 2020 Sep; 8(9):863-872. PubMed ID: 32243865
[TBL] [Abstract][Full Text] [Related]
6. An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation.
Floria M; Oancea AF; Morariu PC; Burlacu A; Iov DE; Chiriac CP; Baroi GL; Stafie CS; Cuciureanu M; Scripcariu V; Tanase DM
Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675178
[TBL] [Abstract][Full Text] [Related]
7. [The hemodynamic effects of a treatment with beta-receptor blockers during coronary surgery. A comparison between acebutolol and esmolol].
Kling D; Boldt J; Zickmann B; Dapper F; Hempelmann G
Anaesthesist; 1990 May; 39(5):264-8. PubMed ID: 1972611
[TBL] [Abstract][Full Text] [Related]
8. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.
Morelli A; Ertmer C; Westphal M; Rehberg S; Kampmeier T; Ligges S; Orecchioni A; D'Egidio A; D'Ippoliti F; Raffone C; Venditti M; Guarracino F; Girardis M; Tritapepe L; Pietropaoli P; Mebazaa A; Singer M
JAMA; 2013 Oct; 310(16):1683-91. PubMed ID: 24108526
[TBL] [Abstract][Full Text] [Related]
9. Esmolol for septic shock: more than just heart rate control?
Orbegozo Cortes D; Njimi H; Dell'Anna AM; Taccone FS
Minerva Anestesiol; 2014 Feb; 80(2):254-8. PubMed ID: 24500140
[TBL] [Abstract][Full Text] [Related]
10. The role of beta-blockers in septic patients.
Hamzaoui O; Teboul JL
Minerva Anestesiol; 2015 Mar; 81(3):312-9. PubMed ID: 24941896
[TBL] [Abstract][Full Text] [Related]
11. Systolic-dicrotic notch pressure difference can identify tachycardic patients with septic shock at risk of cardiovascular decompensation following pharmacological heart rate reduction.
Morelli A; Romano SM; Sanfilippo F; Santonocito C; Frati G; Chiostri M; Agrò FE; Ertmer C; Rehberg SW; Vieillard-Baron A
Br J Anaesth; 2020 Dec; 125(6):1018-1024. PubMed ID: 32690246
[TBL] [Abstract][Full Text] [Related]
12. Beta-blockers in septic shock: What is new?
Lescroart M; Pequignot B; Kimmoun A; Klein T; Levy B
J Intensive Med; 2022 Jul; 2(3):150-155. PubMed ID: 36789018
[TBL] [Abstract][Full Text] [Related]
13. Sepsis Care Pathway 2019.
Labib A
Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
[No Abstract] [Full Text] [Related]
14. [Effect of esmolol in septic shock patients with tachycardia: a randomized clinical trial].
Liu H; Ding XF; Zhang SG; Wang HX; Luo YG; Duan XG; Liu SH; Zhang RF; Zhang XJ; Qin CH; Han B; Wang Y; Sun TW
Zhonghua Yi Xue Za Zhi; 2019 May; 99(17):1317-1322. PubMed ID: 31091579
[No Abstract] [Full Text] [Related]
15. Premorbid β1-selective (but not non-selective) β-blocker exposure reduces intensive care unit mortality among septic patients.
Kuo MJ; Chou RH; Lu YW; Guo JY; Tsai YL; Wu CH; Huang PH; Lin SJ
J Intensive Care; 2021 May; 9(1):40. PubMed ID: 33985572
[TBL] [Abstract][Full Text] [Related]
16. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis.
Okajima M; Takamura M; Taniguchi T
World J Crit Care Med; 2015 Aug; 4(3):251-7. PubMed ID: 26261777
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature.
Matsuishi Y; Mathis BJ; Shimojo N; Kawano S; Inoue Y
Vasc Health Risk Manag; 2020; 16():111-123. PubMed ID: 32308404
[TBL] [Abstract][Full Text] [Related]
18. [Beta-blockers in Septic Shock].
Uhlig C; Spieth PM
Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Nov; 53(11-12):787-792. PubMed ID: 30458576
[TBL] [Abstract][Full Text] [Related]
19. Esmolol Administration to Control Tachycardia in an Ovine Model of Peritonitis.
Hosokawa K; Su F; Taccone FS; Post EH; Pereira AJ; Herpain A; Creteur J; Vincent JL
Anesth Analg; 2017 Dec; 125(6):1952-1959. PubMed ID: 28708664
[TBL] [Abstract][Full Text] [Related]
20. [New ultra-short-acting beta-blockers: landiolol and esmolol--the effects on cardiovascular system].
Mio Y
Masui; 2006 Jul; 55(7):841-8. PubMed ID: 16856544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
